Abstract: The invention relates to recombinant lactobacillus, use of the same and a pharmaceutical composition including the same. The recombinant lactobacillus includes a heterologous nucleic acid sequence. The heterologous nucleic acid sequence encodes at least an immunogenic fragment of the mite allergens Der p 1, Der p 2, or Blo t 5, or an immunogenic homolog thereof. A respective fragment of Der p 1 includes at least 8% of the amino acid sequence of the mite allergen. A method of modulating the immune response to an allergen in a mammal as well as a pharmaceutical composition and a kit are also disclosed.

Abstract: The present invention relates generally to the identification of the products of gene expression in cancerous tissue or other tissue associated with an aberrant medical condition. Identification of such expression products enables the development of a range of diagnostic and therapeutic agents. In one embodiment of the present invention, a gene is differentially or preferentially expressed in cancerous tissue relative to normal tissue. Identification of the expression product of the gene and of the gene itself provides a means of developing diagnostic and therapeutic agents for the treatment, prophylaxis, and diagnosis of the cancerous condition in which the gene is differentially or preferentially expressed.